Anti-Myeloperoxidase Antibodies Associate with Future Proliferative Lupus Nephritis

Table 2

The percent PLN patients with MPO-ANCA above specific thresholds compared to matching healthy and SLE without LN disease controls. The Department of Defense Serum Repository could not assign a matching disease control for one patient. The samples for a second control were lost in processing. Not all patients had samples available for each subgroup time period. If multiple serum samples were present for a patient in a specific subgroup analysis time period, the highest antibody level dictated group assignment. due to actual infinite value.

(a)

MPO-ANCA	Cases; (%)	Healthy controls; (%)	OR; (odds ratio)	CI; (confidence interval)	value; (Fisher’s exact)
(≥3 U/mL):
All	91 (21/23)	26 (6/23)	30	5.3–167	<0.001
<1 year	88 (15/17)	19 (3/16)	33	4.7–226	<0.001
1–4 years	87 (13/15)	13 (2/15)	42	5.2–347	<0.001
>4 years	69 (11/16)	25 (4/16)	6.6	1.4–31	0.03
(≥6 U/mL)
All	57 (13/23)	0 (0/23)			<0.001
<1 year	59 (10/17)	0 (0/16)			<0.001
1–4 years	7 (1/15)	0 (0/15)			1.0
>4 years	19 (3/16)	0 (0/16)			0.23

(b)

MPO-ANCA	Cases; (%)	Disease controls; (%)	OR; (odds ratio)	CI; (confidence interval)	value; (Fisher’s exact)
(≥3 U/mL):
All	91 (21/23)	43 (9/21)	14	2.6–76	<0.001
<1 year	88 (15/17)	39 (5/13)	12	1.9–76	0.007
1–4 years	87 (13/15)	38 (6/16)	11	1.8–66	0.009
>4 years	69 (11/16)	44 (7/16)	2.8	0.7–12	0.29
(≥6 U/mL)
All	57 (13/23)	5 (1/21)	26	3.0–228	<0.001
<1 year	59 (10/17)	8 (1/13)	17	1.8–164	0.006
1–4 years	7 (1/15)	6 (1/16)	1.1	0.1–19	1.0
>4 years	19 (3/16)	0 (0/16)		0.5–	0.23